Home / Awards / Global Generics & Biosimilars Awards 2025

SPONSORED BY

ABOUT THIS AWARD

The Global Generics & Biosimilars Awards 2025 return to Frankfurt for the 12th anniversary!

Join us in Frankfurt during CPhI Worldwide week to commemorate the 12th anniversary of the Global Generics & Biosimilars Awards—a prestigious recognition of outstanding achievements and transformative innovations in the global off-patent pharmaceutical industry.

This event shines a spotlight on industry leadership in generics and biosimilars, honouring exceptional contributions across 14 distinguished categories, including Biosimilar Initiative of the Year, Leader of the Year, and API Supplier of the Year. From advancing biosimilars innovation to enhancing pharma manufacturing, these Awards celebrate those shaping the future of generic pharmaceuticals, biosimilar medicines, and value-added medicines.

Key Details:

  • Entry deadline: Friday, 1 August, 2025
  • Ceremony: Wednesday, 29 October, 2025
  • Location: Radisson Blu Hotel, Frankfurt

The Awards represent global recognition of pharmaceutical excellence. The rigorous judging process ensures only the most deserving are celebrated, with winners unveiled at the Awards ceremony on Wednesday, 29 October 2025. Don’t miss this opportunity to honour the visionaries transforming healthcare. Submit your entry today—free of charge—and join us in celebrating the future of off-patent medicines.

2025 PHOTO GALLERY

Acquisition of the Year winner: Hikma Pharmaceuticals Value Added Medicine Initiative of the Year Biosimilar Initiative of the Year winner: Samsung Bioepis Biosimilar Initiative of the Year winner: Samsung Bioepis Business Development of the Year winner: Accord Healthcare Campaign of the Year winner: Association for Accessible Medicines & Biosimilars Council Campaign of the Year winner: Association for Accessible Medicines & Biosimilars Council Company of the Year – Asia-Pacific winner: Aurobindo Company of the Year – EMEA winner: Sandoz Company of the Year winner: Sandoz Corporate Social Responsibility (CSR) Initiative of the Year winner: CNX Therapeutics Industry Partner of the Year winner: Cencora Leader of the Year winner: Richard Saynor, CEO of Sandoz Regulatory Achievement of the Year winner: Sandoz Value Added Medicine Initiative of the Year winner: Adalvo
WANT TO BOOK A HOTEL
THE GLOBAL GENERICS & BIOSIMILARS AWARDS CATEGORIES

WINNER

Sandoz

FINALISTS

  • Adalvo
  • Aurobindo Pharma
  • Hikma Pharmaceuticals
  • Sandoz
  • Samsung Bioepis
  • Synthon

WHO COULD ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.

WHO CAN ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business. Entry eligibility period of 1 August 2024-31 July 2025.

Company of the Year – Americas

WINNER

Amneal

FINALISTS

  • Amneal
  • ANI Pharmaceuticals
  • Viatris

Company of the Year – EMEA

WINNER

Sandoz

FINALISTS

  • Adalvo
  • Hikma Pharmaceuticals
  • Sandoz
  • Synthon

Company of the Year – Asia-Pacific

WINNER

Aurobindo

FINALISTS

  • Aurobindo Pharma
  • JB Chemicals & Pharmaceuticals
  • Samsung Bioepis

WHO COULD ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.

WINNER

Hikma Pharmaceuticals

FINALISTS

  • Adalvo
  • Aurobindo Pharma
  • Hikma Pharmaceuticals
  • Synthon

WHO COULD ENTER

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.

WINNER

Richard Saynor, CEO of Sandoz

FINALISTS

  • Enrico Zodio, CEO of Procos
  • Anish Mehta, CEO of Synthon
  • Stephen Beckman, CEO of YARAL Pharma, Inc.
  • Ankur Shah, Chairman and Managing Director of Invengene Private
  • Riad Mishlawi, CEO of Hikma Pharmaceuticals
  • Anil Okay, CEO and Founder of Adalvo
  • Richard Saynor, CEO of Sandoz
  • Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis
  • Mr. V Muralidharan (Murali), CEO of Aurobindo Pharma's European business

WHO COULD ENTER

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.

WINNER

Accord Healthcare

FINALISTS

  • Accord Healthcare
  • Adalvo
  • Invengene Private
  • Sandoz
  • Samsung Bioepis
  • Shanghai Henlius Biotech
  • Synthon

WHO COULD ENTER

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.

WINNER

Samsung Bioepis

FINALISTS

  • Adalvo
  • Celltrion
  • Samsung Bioepis
  • Sandoz

WHO COULD ENTER

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.

WINNER

Sandoz

FINALISTS

  • Adalvo
  • DDReg Pharma Private
  • Lloyds Clinical
  • Sandoz
  • Veranova

WHO COULD ENTER

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.

WINNER

CNX Therapeutics

FINALISTS

  • Adalvo
  • Cencora
  • Centrient
  • CNX Therapeutics
  • Procos S.P.A

WHO COULD ENTER

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, training & education programmes, compulsory licensing and humanitarian aid donations.

WINNER

Cencora

FINALISTS

  • Synthon partnership with Accord Healthcare
  • Adalvo
  • Cencora
  • Invengene Private
  • JB Chemicals & Pharmaceuticals

WHO COULD ENTER

Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract manufacturers, law firms and consultants.

WINNER

Association for Accessible Medicines & Biosimilars Council

FINALISTS

  • Association for Accessible Medicines & Biosimilars Council
  • Biosimilars Canada
  • International Generic and Biosimilar medicines Association
  • JB Chemicals & Pharmaceuticals
  • Spanish biosimilar medicines association BioSina

WHO COULD ENTER

This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.

BOOK YOUR TABLE FOR THE AWARDS ON WEDNESDAY, 29 OCTOBER, 2025
OUR 2025 SPONSORS
Adalvo
Adalvo is a leading B2B pharmaceutical company in Europe with over 140 global partners in 143+ countries. The company's goal is to improve patient care by providing high-quality products and services through a smart collaboration network. Adalvo's unique approach is tailored to each partner, helping them grow their business and achieve their objectives, whether that's increasing revenue or expanding into new markets. The company also prioritizes employee development and community growth while striving for excellence. Adalvo's commitment to excellence and making a difference ensures that it remains a key player in the competitive pharmaceutical industry.
Aurobindo
Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.

The company that started less than four decades ago as a single unit manufacturing Semi-Synthetic Penicillin (SSP) has now grown into a $ 3.5 billion global business with presence in over 150 countries and in all major therapeutic segments; API, FDF, Biocatalysts , Vaccines, Peptides and Biologicals.

With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs in India.
Parsity Group
Parsity Group is a global executive search partner specialising in the pharmaceutical industry, with expertise in generics, biosimilars, and specialty pharmaceuticals. With a presence in the UK, Germany, Belgium, Czechia, and the US, we support clients in over 60 countries, securing exceptional leadership talent. Our consultants average 15+ years of experience, backed by research capability and advanced CRM tools. We offer an unrivalled candidate network and high engagement rates. Learn more about how we can strengthen your organisation www.parsitygroup.com
Pharmacloud
Pharmacloud was founded in 2009 to offer bespoke research and consulting services and today is one of the leading European providers of specialist commercial due diligence on generic and mature brand pharmaceutical companies, as well as CMOs, CDMOs, dossier developers and API manufacturers. In addition, to commercial due diligence, Pharmacloud offers strategic consulting services to both pharma company and private equity clients.
Pharmawise
Pharmawise is a leading boutique consulting firm focused on generic and biosimilar market expertise. Since 2006, we have conducted 150+ projects for leading financial institutions, generic and pharmaceutical companies, spanning:

  • due-diligence, acquisition screening and post-deal support

  • portfolio optimization and pipeline design or selection

  • mature brand strategy and life cycle management

  • product or portfolio in-licensing and out-licensing

  • quality, pharmacovigilance and regulatory audits

  • operational and supply chain optimization

  • product and process development

  • organizational design and culture

  • intellectual property and patents

  • strategy development


We match deep know-how and know-who to your generic or biosimilar needs: our project teams include highly knowledgeable experts with ~20 years executive experience and networks at successful global or local generic companies and leading management consulting firms in the above-mentioned areas.

If your responsibilities match our expertise, we would love to hear from you. Contact us at www.pharma-wise.com
Sandoz
Sandoz is the global leader in generic and biosimilar medicines, with a strategy driven by its Purpose: pioneering access for patients. We provide over 900 million patient treatments annually, generating substantial healthcare savings and an even larger social impact. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886.
OUR 2025 SUPPORTERS
IGBA
The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org
IHP
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
Pharma Ignite
Pharma Ignite brings you the most up-to-date and informed intelligence in the industry. Our network of industry-leading analysts and partners is pursuing new intelligence in the core areas of life sciences using Citeline’s suite of insights products and services - all of which has the power to fuel your organization and projects.

We provide cutting-edge lead generation and brand programmes to help you reach and collaborate with audiences across industry events and digital platforms.
JUDGES
''
JIM KEON
President
Canadian Generic Pharmaceutical Association
''
EWAN LIVESEY
Founder and Managing Director
Birnam Oak Consultancy
''
AXEL MULLER
Associate Partner
Fidelio Healthcare Partners
Picture of Lily Jones-Herbst
LILY JONES-HERBST
Corporate Partnerships Manager
IHP
Unknown
REBECCA GRAHAM
Business Development Officer
IHP
Headshot photo of John Murphy
JOHN MURPHY, III
President and CEO
Association of Accessible Medicines (AAM)
Headshot image of James Vane-Tempest
JAMES VANE-TEMPEST
Managing Director
Jefferies International
Headshot image of Alex Keeton
ALEX KEETON
Senior Vice President of Policy
Association for Accessible Medicines
Headshot image of Susana Almeida
SUSANA ALMEIDA, PhD
Secretary General
IGBA
JIM KEON
President
  Canadian Generic Pharmaceutical Association
Jim Keon is President of the Canadian Generic Pharmaceutical Association (CGPA), and President of Biosimilars Canada organizations representing Canada’s generic and biosimilar pharmaceutical sectors.
EWAN LIVESEY
Founder and Managing Director
 Birnam Oak Consultancy
Ewan is corporate and business development leader and qualified lawyer with over 25 years’ experience in the pharmaceutical industry with roles ranging from General Counsel to Chief Business Officer for global pharmaceutical companies. He has worked for some of the leading generic companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva where he led the acquisition of Alvogen’s CEE business (acquisition of the year 2020).
AXEL MULLER
Associate Partner
 Fidelio Healthcare Partners
Axel Müller - by education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013.
LILY JONES-HERBST
Corporate Partnerships Manager
 IHP
Lily is the Corporate Partnerships Manager for International Health Partners UK. In this role, she is responsible for overseeing the product donations process for the Corporate Partnerships Team and the account management of IHP’s 40+ partners.

Lily’s background started in the private sector working as a Business Consultant. After achieving her Master’s degree in International Development, Lily went on to work for a social enterprise start-up, promoting and supporting multi-sector and multi-stakeholder partnerships to deliver impact on the Sustainable Development Goals and to improve humanitarian action. Lily quickly developed a passion for private sector partnerships and went on to join the Corporate Partnerships Team at International Health Partners in September 2020.
REBECCA GRAHAM
Business Development Officer
 IHP
JOHN MURPHY, III
President and CEO
 Association of Accessible Medicines (AAM)
John Murphy is the President and CEO of the Association of Accessible Medicines (AAM), the preeminent global trade association representing the prescription generics and biosimilars industry. Under his leadership, AAM is dedicated to enhancing access to safe, high-quality, and affordable medication for all patients in need. John is at the forefront of AAM’s efforts to foster a sustainable and resilient supply chain for generics and biosimilars, while continuously striving to broaden the range of affordable medication options available globally from AAM members.

He previously served as Chief Policy Officer and Senior Healthcare Counsel at the Biotechnology Innovation Organization (BIO), where he led domestic and international policy initiatives and directed the legal affairs of BIO’s healthcare division.

John holds degrees from Villanova University and the Catholic University Columbus School of Law. His career also includes experience in healthcare regulatory and enforcement matters at Hogan Lovells, LLP, as well as serving as Assistant General Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA).
JAMES VANE-TEMPEST
Managing Director
 Jefferies International
James Vane-Tempest is a Managing Director at Jefferies International, a Global Investment Bank, and heads the European Healthcare equity research team. James has 22 years industry experience and has covered the Generics sector for 15 years.  In 2017, James was named #1 stock picker in the UK across all sectors in the Thomson Reuters Analyst Awards and in 2022 & 2023 was a Runner Up in the Institutional Investor Survey. James has a BSc Integrated degree in Physiology with Business from The University of Edinburgh.
ALEX KEETON
Senior Vice President of Policy
 Association for Accessible Medicines
SUSANA ALMEIDA, PhD
Secretary General
 IGBA
Dr. Susana Almeida was nominated Secretary General of the International Generic and Biosimilar medicines Association (IGBA) in January 2024.

With over 20 years of substantial contribution to the role of the European and international generic and biosimilar medicines industry’s trade bodies and companies, Susana also brings significant experience in the process of international harmonisation of standards through the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Before joining the IGBA, Susana was Clinical Development and Safety Director at Medicines for Europe. She has also worked in clinical trials and pharmacovigilance in Europe and in North America, and her experience includes the pharmaceutical industry and clinical research organizations.

Susana is a firm believer that the generic and biosimilar medicines industries play a vital role in fostering worldwide patient access to quality-assured medicines and that a strong off patent sector is essential to a healthy medicines ecosystem

She holds a PhD in Clinical Pharmacology from the Faculty of Medicine, Universidad Autònoma de Barcelona (UAB), Spain (2011) and has authored several scientific papers and patents.
NEXT STEPS
Sponsorship Opportunities
Sponsorship of the 12th Global Generics & Biosimilars awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.
Register your place
Looking to attend the Global Generics & Biosimilars Awards? Register for your FREE place today

PREVIOUS GLOBAL GENERICS & BIOSIMILARS AWARD CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
GGB Awards 2024 poster announcement with date and location details. The event will be on October 9, 2024 at Hotel NH Milano Fiera.
Commercial

Global Generics & Biosimilars Awards 2024

Hotel NH Milano Fiera
Join us in celebrating the 11th anniversary of the Global Generics and Biosimilars Awards in Milan, honouring outstanding achievements and innovations in the global off-patent pharma industry.

 JUL 22, 2024

Headline sponsor

Company logo of IQVIA
Global Generics & Biosimilars image poster
Clinical

Global Generics & Biosimilars Awards 2023

Hotel Porta Fira, Barcelona
Celebrate a decade of excellence at the Global Generics and Biosimilars Awards and honour the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA
Abstract blue and green spiral.
Clinical

Global Generics and Biosimilars Awards 2022

Frankfurt Marriott Hotel
The Global Generics and Biosimilars Awards honor the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA